Trial Profile
Phase II Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Aug 2022
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Giant cell tumour of tendon sheath; Pigmented villonodular synovitis
- Focus Therapeutic Use
- Acronyms PVNS
- 03 Aug 2022 Results assessing long-term outcome of nilotinib in patients with advanced tenosynovial giant cell tumours, published in the European Journal of Cancer.
- 18 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database
- 29 Mar 2018 New trial record